Sunday, 20 September 2026European Markets

ORAPI Stock Bullish Momentum With A 12% Rise So Far Today

Loading stream...

orapi stocks made an impressive rebound on tuesday morning by increasing 12.32% to eur6.38, effectively ending their four consecutive days of losses and displaying a strong sense of resilience against bearish market sentiment. meanwhile, the cac 40 experienced a minor dip of 0.45% after two consecutive sessions of gains, presenting some bearish indicators in terms of its performance on the day. it's notable to mention that the orapi stock currently trades 1.73% below its 52-week high of eur5.78.

about the company

hexotol, the parent company of orapi, is based out of saint-vulbas, france, and operates on a global scale across a variety of sectors. these sectors include health care, industrial manufacturing, transport, leisure activities, local authorities and cleaning. they offer a diverse range of products under various brands, including cleaners, adhesives, lubricants, personal protective equipment (ppe), and a selection of specialty products. their signature brands include hexotol, orapi hygiene process, orapi process proven proven transnet, among others.

financial performance

in terms of financial performance, orapi has reported trailing twelve-month earnings per share (eps) of eur0.12. the price-to-earnings (pe) ratio currently stands at 53.17, indicating that an investor would be required to invest eur53.17 for every euro of annual earnings. furthermore, the roe, which measures profitability relative to shareholders' equity, reached 1.53% over this same time frame.

recent trading volume and revenue

it seems as if orapi has succeeded in regaining the trust of investors, as evidenced by its most recent recorded trading volume. the volume was recorded at 14,491 – an increase of 187% over average volumes. however, in terms of revenue, the picture isn't as rosy. unfortunately, the year-on-year quarterly revenue growth decreased by 14.3% with revenue currently standing at 229.6m for the trailing twelve months.

investor outlook

moving forward, the recent surge in orapi's price appears to indicate a surge in investor optimism regarding the company's future performance. however, it's prudent for investors to consider the decrease in quarterly revenue growth over time. market trends are in a constant state of flux, making it crucial for investors to stay on top of market developments. thorough consideration should be given to all potential variables before making financial decisions.

more news about orapi (orap.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com